47 research outputs found

    COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study

    Get PDF
    Background: The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships of age, sex, and nationality to presenting symptoms. Methods: International, prospective observational study of 60 109 hospitalized symptomatic patients with laboratory-confirmed COVID-19 recruited from 43 countries between 30 January and 3 August 2020. Logistic regression was performed to evaluate relationships of age and sex to published COVID-19 case definitions and the most commonly reported symptoms. Results: ‘Typical’ symptoms of fever (69%), cough (68%) and shortness of breath (66%) were the most commonly reported. 92% of patients experienced at least one of these. Prevalence of typical symptoms was greatest in 30- to 60-year-olds (respectively 80, 79, 69%; at least one 95%). They were reported less frequently in children (≀ 18 years: 69, 48, 23; 85%), older adults (≄ 70 years: 61, 62, 65; 90%), and women (66, 66, 64; 90%; vs. men 71, 70, 67; 93%, each P < 0.001). The most common atypical presentations under 60 years of age were nausea and vomiting and abdominal pain, and over 60 years was confusion. Regression models showed significant differences in symptoms with sex, age and country. Interpretation: This international collaboration has allowed us to report reliable symptom data from the largest cohort of patients admitted to hospital with COVID-19. Adults over 60 and children admitted to hospital with COVID-19 are less likely to present with typical symptoms. Nausea and vomiting are common atypical presentations under 30 years. Confusion is a frequent atypical presentation of COVID-19 in adults over 60 years. Women are less likely to experience typical symptoms than men

    Impact of Age-related Comorbidities on Five-year Overall Mortality among Elderly HIV-Infected Patients in the Late HAART Era--Role of Chronic Renal Disease.

    No full text
    International audienceTo identify main prognostic factors for 5-year mortality among age-related comorbidities (ARCs) in older people living with HIV (PLHIV).A prospective, multicentre cohort study with a 5-year follow-up period in the late HAART era (from January 2008 to December 2012).The Dat'AIDS cohort involving 12 French hospitals.All actively followed HIV-1 infected patients aged 60 or older.The study endpoint was all-cause five-year mortality. The following ARCs were considered: chronic renal disease, cardiovascular diseases, cancer, chronic pulmonary disease, cirrhosis, diabetes and nutritional status. Hepatitis C (HCV), hepatitis B (HBV) co-infection and sociodemographic characteristics were also evaluated. Cox's Proportional Hazards model was used for multivariate analysis.Among 1415 PLHIV aged 60 or more patients included, mean age was 66±5.5 years; 154 died (mortality rate 2.47/100 patient-years). The most prevalent ARCs were chronic renal disease (20.1%), diabetes (14.2%) and cardiovascular diseases (12.2%). By multivariate analysis, chronic renal disease (adjusted hazard ratio (aHR)=2.25; 95% confidence interval (CI) [1.58-2.21]; p<10-4), cardiovascular diseases (aHR=2.40; 95%CI[1.64-3.52]; p<10-4), non-HIV related cancer (aHR=1.91; 95%CI[1.20-3.05]; p=0.007), cirrhosis (aHR=2.99; 95%CI[1.68-5.33]; p<10-3), HCV co-infection (aHR=2.00; 95%CI[1.18-3.38]; p=0.009), low body mass index (aHR=2.42; 95%CI[1.46-4.01]; p<10-3) and CD4 cell count < 200 cells/”l (aHR=2.23; 95%CI[1.36-3.65]; p=0.002) were independently associated with 5 year mortality.Due to a high prevalence, chronic renal disease and cardiovascular disease are main prognostic factors for 5-year mortality among aged PLHIV

    Pseudo pyoderma gangrenosum Ă  Scedosporium apiospermum

    No full text
    International audienc

    COL 3-02 - Les comorbiditĂ©s liĂ©es Ă  l’ñge sont associĂ©es Ă  l’excĂšs de mortalitĂ© liĂ© au VIH chez les patients vivant avec le VIH de 60 ans et plus dans la cohorte Dat’AIDS

    No full text
    National audienceIntroduction Depuis le dĂ©but de l’ùre des traitements antirĂ©troviraux hautement actifs, les patients vivant avec le VIH (PVVIH) vieillissent. Les comorbiditĂ©s liĂ©es Ă  l’ñge (CLA) deviennent des causes grandissantes de mortalitĂ© dans cette population.L’objectif de cette Ă©tude Ă©tait d’évaluer leur impact sur la surmortalitĂ© liĂ©e au VIH sur 5 ans chez les PVVIH ĂągĂ©s de 60 ans ou plus suivis dans le cadre d’une large cohorte prospective multicentrique française (Dat’AIDS) Ă  l’ùre tardive des antirĂ©troviraux hautement actifs (du 01/01/2008 au 31/12/2012)
    corecore